Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT04335604 Completed - Clinical trials for Advanced Solid Tumors

A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors

Start date: December 6, 2017
Phase: Phase 1
Study type: Interventional

To assess the Safety, Tolerability, and Pharmacokinetic-pharmacodynamic Profile and efficacy of JPI-547 in patients with advanced solid tumor.

NCT ID: NCT04335253 Completed - Advanced Cancer Clinical Trials

First-In-Human Study of EOS884448 in Participants With Advanced Cancers.

Start date: February 18, 2020
Phase: Phase 1
Study type: Interventional

IO-002 study is a multicenter, open-label, dose-escalation Phase I/IIa clinical study to evaluate the safety and tolerability, PK, PD, and antitumor activity of EOS884448 in participants with advanced cancers.

NCT ID: NCT04332419 Completed - Clinical trials for Hepatic Malignancies

Comparison of Yttrium-90 Absorbed Doses Using PET/CT Versus PET/MR Imaging for Hepatic Malignancies

Start date: March 3, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the results of positron emission tomography/computer tomography (PET/CT) to positron emission tomography/magnetic resonance imaging (PET/MRI) to help determine any added advantage of one over the other in relation to a tumor which might assist in further management plans.

NCT ID: NCT04328831 Completed - Clinical trials for Advanced Malignancies

Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors

Start date: July 31, 2020
Phase: Phase 1
Study type: Interventional

This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in cancer subjects who failed standard treatment.

NCT ID: NCT04327063 Completed - Clinical trials for Malignant Neoplasm of Breast

MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery

Start date: August 4, 2020
Phase: Phase 3
Study type: Interventional

Compare the effect of ropivacaine versus placebo pectoral nerve block (Pecs 1 and 2) on acute pain after tumorectomy plus sentinel lymph node dissection on one day surgery.

NCT ID: NCT04324814 Completed - Clinical trials for Advanced Solid Tumor

A Trial of SHR-1701 in Subjects With Advanced Solid Tumors

Start date: March 31, 2020
Phase: Phase 1
Study type: Interventional

This is a dose-escalation and dose-expansion Phase 1 trial to evaluate the safety and tolerability of SHR-1701 in subjects with advanced solid tumors.

NCT ID: NCT04324645 Completed - Radiation Therapy Clinical Trials

Active Symptom Monitoring in Patients Undergoing Radiation Therapy for Thoracic Malignancies

Start date: September 3, 2020
Phase:
Study type: Observational

This study seeks to achieve two aims: - To assess the implementation of Noona software for continuous symptom monitoring for a diverse population of patients with thoracic malignancies who are undergoing radiation and - To validate remote collection of standardized PRO measures using Noona software.

NCT ID: NCT04324372 Completed - Clinical trials for Advanced Refractory Solid Tumors

Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors

Start date: February 27, 2019
Phase: Phase 1
Study type: Interventional

Clinical study of HEC68498 in patients with advanced refractory solid tumors. The primary objective is to determine the maximum tolerated dose and dose limiting toxicity of HEC68498 in patients with advanced refractory solid tumors

NCT ID: NCT04322552 Completed - Clinical trials for Advanced Solid Tumor

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects

Start date: March 12, 2020
Phase: Phase 1
Study type: Interventional

Apatinib, an oral inhibitor of vascular endothelial growth factor receptor 2#VEGFR-2#, Induces Transporter Pgp function in vitro. This study in patients with advanced cancer evaluated the effect of Apatinib on Transporter Pgp function by comparing the pharmacokinetics of Transporter Pgp-specific probe drugs in the presence and absence of Apatinib. The probes used Substrate Digoxin.

NCT ID: NCT04317781 Completed - Clinical trials for Blastic Plasmacytoid Dendritic Cell Neoplasm

Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant

Start date: March 27, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects of tagraxofusp in treating patients with blastic plasmacytoid dendritic cell neoplasm after stem cell transplant. Tagraxofusp is a type of immunotoxin that is made by linking a protein called IL-3 to a toxic substance. Tagraxofusp may help find cancer cells that express IL-3 and kill them without harming normal cells.